氯吡格雷双倍剂量对冠脉介入术后氯吡格雷抵抗患者缺血及出血事件的影响

目的 评价经皮冠状动脉介入治疗(PCI)后,氯吡格雷抵抗患者服用双倍剂量氯吡格雷的有效性及安全性.方法 依据血栓弹力图(TEG)的测定结果,将入选的134例氯吡格雷抵抗患者分为常规剂量组67例与双倍剂量组67例,随访观察两组患者PCI术后6个月时临床缺血及出血事件的发生率.结果 双倍剂量组与常规剂量组患者相比较,主要不良心血管事件的发生率明显降低,而出血事件发生率在两组患者间比较,差异无统计学意义.结论 增加氯吡格雷的维持剂量,可以减少冠心病患者PCI术后缺血事件的发生,且不增加患者的出血风险.

The influence of double dose clopidogrel to the ischemic and bleeding events of patients with clopidogrel resistance undergoing percutaneous coronary intervention

Objective To evaluate the efficiency and safety of the patients with clopidogrel resistance prescibed with double dose clopidogrel undergoing percutaneous coronary intervention(PCI).Methods 134 patients with clopidogrel resistance were divided into routine dose group(67 cases) and double dose group(67 cases) according to the result of thromboelastography(TEG),the incidence of the ischemic and bleeding events of two group patients were followed up during in hospital stay and clinical of 6 months after operation.Results Compared with the routine dose group,the incidence of major adverse cardiac events was significantly lower in the double dose group.And there were no significant differences in the incidence of bleeding events between two groups.Conclusions Our data indicates that the incidence of ischemic events of patients with coronary heart disease undergoing PCI may be decreased by increasing the maintenance dose of clopidogrel,and the risk of bleeding may be not increased.